{"pmid":32409439,"title":"Practical aspects of targeting IL-6 in COVID-19 disease.","text":["Practical aspects of targeting IL-6 in COVID-19 disease.","Severe cases of COVID-19 are often attended by a syndrome that has been described as \"cytokine storm,\" with some features shared with macrophage activation syndrome. A variety of experimental therapies targeting this hyperinflammatory state are now being applied in hospitals around the world. Among the most widely used treatments are monoclonal antibodies targeting interleukin-6 (IL-6) or the IL-6 receptor. Anti-IL-6 drugs are being widely used experimentally and as off-label therapy for patients with COVID-19 who are sick and deteriorating but have a reasonable chance of recovering, but they are still unproven and unapproved for this use. The pandemic has created major ethical and practical questions about patient selection and nonapproved use vs use in the context of a randomized clinical trial.","Cleve Clin J Med","Calabrese, Cassandra","Rajendram, Prabalini","Sacha, Gretchen","Calabrese, Leonard","32409439"],"abstract":["Severe cases of COVID-19 are often attended by a syndrome that has been described as \"cytokine storm,\" with some features shared with macrophage activation syndrome. A variety of experimental therapies targeting this hyperinflammatory state are now being applied in hospitals around the world. Among the most widely used treatments are monoclonal antibodies targeting interleukin-6 (IL-6) or the IL-6 receptor. Anti-IL-6 drugs are being widely used experimentally and as off-label therapy for patients with COVID-19 who are sick and deteriorating but have a reasonable chance of recovering, but they are still unproven and unapproved for this use. The pandemic has created major ethical and practical questions about patient selection and nonapproved use vs use in the context of a randomized clinical trial."],"journal":"Cleve Clin J Med","authors":["Calabrese, Cassandra","Rajendram, Prabalini","Sacha, Gretchen","Calabrese, Leonard"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409439","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3949/ccjm.87a.ccc018","topics":["Treatment"],"weight":1,"_version_":1666897319149174785,"score":9.490897,"similar":[{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":153.84453},{"pmid":32378647,"title":"Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?","text":["Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?","The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of \"cytokine storm\" in COVID-19. However, we still lack reliable studies to verify \"cytokine storm\" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated.","Drug Discov Ther","Zhang, Yuanyuan","Zhong, Yanyan","Pan, Lin","Dong, Jing","32378647"],"abstract":["The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of \"cytokine storm\" in COVID-19. However, we still lack reliable studies to verify \"cytokine storm\" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated."],"journal":"Drug Discov Ther","authors":["Zhang, Yuanyuan","Zhong, Yanyan","Pan, Lin","Dong, Jing"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378647","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.5582/ddt.2020.03006","keywords":["coronavirus","cytokine storm","pneumonia","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097302917120,"score":147.61966},{"pmid":32472655,"title":"Cytokine storm in COVID-19 and parthenolide: preclinical evidence.","text":["Cytokine storm in COVID-19 and parthenolide: preclinical evidence.","A group of patients with pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported from China in December 2019. Although several antiviral drugs are widely tested, none of them has been approved as specific antiviral therapy for coronavirus disease 2019 (COVID-19). Accumulating evidence established a hyperinflammatory states or cytokine storm in COVID-19. Among these cytokines, IL-6 plays a key role in cytokine storm and can predict the adverse clinical outcomes and fatality in these patients. Based on the evidence of the significant role of IL-6 in cytokine storm, diabetes mellitus and cardiovascular diseases as principal comorbidities, it seems that anti-cytokine therapy may be useful in patients with severe COVID-19 to reduce mortality. Recent studies demonstrated that herbal-derived natural products had immunosuppressive and anti-inflammatory properties and exhibited exceptional act on mediators of inflammation. Parthenolide is the principal sesquiterpene lactones and the main biologically active constituent Tanacetum parthenium (commonly known as feverfew) which has could significantly reduce IL-1, IL-2, IL-6, IL-8, and TNF-alpha production pathways established in several human cell line models in vitro and in vivo studies. Therefore, parthenolide may be one of the herbal candidates for clinical evaluation. This article is protected by copyright. All rights reserved.","Phytother Res","Bahrami, Mohsen","Kamalinejad, Mohammad","Latifi, Seied Amirhossein","Seif, Farhad","Dadmehr, Majid","32472655"],"abstract":["A group of patients with pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported from China in December 2019. Although several antiviral drugs are widely tested, none of them has been approved as specific antiviral therapy for coronavirus disease 2019 (COVID-19). Accumulating evidence established a hyperinflammatory states or cytokine storm in COVID-19. Among these cytokines, IL-6 plays a key role in cytokine storm and can predict the adverse clinical outcomes and fatality in these patients. Based on the evidence of the significant role of IL-6 in cytokine storm, diabetes mellitus and cardiovascular diseases as principal comorbidities, it seems that anti-cytokine therapy may be useful in patients with severe COVID-19 to reduce mortality. Recent studies demonstrated that herbal-derived natural products had immunosuppressive and anti-inflammatory properties and exhibited exceptional act on mediators of inflammation. Parthenolide is the principal sesquiterpene lactones and the main biologically active constituent Tanacetum parthenium (commonly known as feverfew) which has could significantly reduce IL-1, IL-2, IL-6, IL-8, and TNF-alpha production pathways established in several human cell line models in vitro and in vivo studies. Therefore, parthenolide may be one of the herbal candidates for clinical evaluation. This article is protected by copyright. All rights reserved."],"journal":"Phytother Res","authors":["Bahrami, Mohsen","Kamalinejad, Mohammad","Latifi, Seied Amirhossein","Seif, Farhad","Dadmehr, Majid"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32472655","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/ptr.6776","keywords":["covid-19","coronavirus","feverfew","parthenolide","tanacetum parthenium"],"locations":["China","Tanacetum","Cytokine"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193360236545,"score":142.05777},{"pmid":32233018,"title":"Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.","text":["Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.","A novel RNA betacoronavirus causing coronavirus disease 2019 (Covid-19) has now been declared pandemic disease by WHO. Guo et al published the first report of biochemical features in patients with diabetes and the further risk that this disease can determine to the progression of Covid-19. Among different cytokines found significantly higher in patients with diabetes compared to those without, Interleukin-6 (IL-6), which is already increased in conditions of chronic inflammation, may play a more deleterious role in Covid-19 infection. Targeting the overexpression of Il-6 effects with a monoclonal antibody against IL-6 receptor or using Janus Kinase inhibitors may be particularly helpful for treatment of Covid-19 pneumonia in diabetes.","Diabetes Metab Res Rev","Maddaloni, Ernesto","Buzzetti, Raffaella","32233018"],"abstract":["A novel RNA betacoronavirus causing coronavirus disease 2019 (Covid-19) has now been declared pandemic disease by WHO. Guo et al published the first report of biochemical features in patients with diabetes and the further risk that this disease can determine to the progression of Covid-19. Among different cytokines found significantly higher in patients with diabetes compared to those without, Interleukin-6 (IL-6), which is already increased in conditions of chronic inflammation, may play a more deleterious role in Covid-19 infection. Targeting the overexpression of Il-6 effects with a monoclonal antibody against IL-6 receptor or using Janus Kinase inhibitors may be particularly helpful for treatment of Covid-19 pneumonia in diabetes."],"journal":"Diabetes Metab Res Rev","authors":["Maddaloni, Ernesto","Buzzetti, Raffaella"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32233018","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1002/dmrr.3321","keywords":["covid-19","diabetes","inflammation; il-6"],"locations":["Janus"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138492195831809,"score":139.59328},{"pmid":32327746,"pmcid":"PMC7178926","title":"Translating IL-6 biology into effective treatments.","text":["Translating IL-6 biology into effective treatments.","In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in health and dysregulation in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arteritis and Takayasu arteritis, as well as other conditions such as Castleman disease and cytokine release syndrome. Targeting this pathway has also identified avenues for potential expansion into several other indications, such as uveitis, neuromyelitis optica and, most recently, COVID-19 pneumonia. To mark the tenth anniversary of anti-IL-6 receptor therapy worldwide, we discuss the history of research into IL-6 biology and the development of therapies that target IL-6 signalling, including the successes and challenges and with an emphasis on rheumatic diseases.","Nat Rev Rheumatol","Choy, Ernest H","De Benedetti, Fabrizio","Takeuchi, Tsutomu","Hashizume, Misato","John, Markus R","Kishimoto, Tadamitsu","32327746"],"abstract":["In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway has emerged as a pivotal pathway involved in immune regulation in health and dysregulation in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches for various rheumatic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disease, giant cell arteritis and Takayasu arteritis, as well as other conditions such as Castleman disease and cytokine release syndrome. Targeting this pathway has also identified avenues for potential expansion into several other indications, such as uveitis, neuromyelitis optica and, most recently, COVID-19 pneumonia. To mark the tenth anniversary of anti-IL-6 receptor therapy worldwide, we discuss the history of research into IL-6 biology and the development of therapies that target IL-6 signalling, including the successes and challenges and with an emphasis on rheumatic diseases."],"journal":"Nat Rev Rheumatol","authors":["Choy, Ernest H","De Benedetti, Fabrizio","Takeuchi, Tsutomu","Hashizume, Misato","John, Markus R","Kishimoto, Tadamitsu"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327746","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1038/s41584-020-0419-z","topics":["Treatment"],"weight":1,"_version_":1666138494751211520,"score":139.29475}]}